Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

(2015) Takashi Kadowaki et al.   ADVANCES IN THERAPY

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus

(2015) E. Araki et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2015) Yutaka Seino et al.   ENDOCRINE JOURNAL

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

(2015) Yutaka Seino et al.   Journal of Diabetes Investigation

Adverse effects and safety of SGLT-2 inhibitors

(2014) S. Halimi et al.   DIABETES & METABOLISM

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

(2014) Lawrence A. Leiter et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

(2014) Nobuya Inagaki et al.   EXPERT OPINION ON PHARMACOTHERAPY

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

(2014) Yukio Tanizawa et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus

(2014) Matthew R. Weir et al.   Journal of Clinical Hypertension

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study

(2014) Nobuya Inagaki et al.   Journal of Diabetes Investigation

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

(2014) Kohei Kaku et al.   Diabetes Therapy

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE